Hyperoxaluria - Pipeline Insight, 2026

This “Hyperoxaluria - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Hyperoxaluria: Understanding

Hyperoxaluria: Overview

Hyperoxaluria is a condition characterized by excessive urinary excretion of oxalate and is a major contributor to the development of kidney stones, particularly Calcium oxalate nephrolithiasis. Renal calculi affect about 10% of the population, and nearly 80% are calcium-based, with calcium oxalate being the most common type. These stones form due to an imbalance between calcium and oxalate levels or a deficiency of natural inhibitors of crystallization such as citrate. Even small increases in urinary oxalate can significantly enhance stone formation, highlighting the clinical importance of maintaining oxalate balance.

Hyperoxaluria may remain asymptomatic in its early stages but most commonly presents with features related to kidney stone formation, particularly Calcium oxalate nephrolithiasis. Patients typically experience recurrent episodes of flank pain or renal colic, which may be severe and radiate to the groin, along with hematuria (blood in urine), dysuria, and increased urinary frequency. Nausea and vomiting often accompany acute stone episodes. Some individuals may notice cloudy or foul-smelling urine due to crystal formation or associated infection.

Hyperoxaluria results from increased oxalate load derived from dietary sources (especially plant-based foods), endogenous liver metabolism, or excess vitamin C conversion. Oxalate is absorbed in the colon, excreted by the kidneys, and in urine it strongly binds calcium to form poorly soluble calcium oxalate crystals, a key factor in Calcium oxalate nephrolithiasis. Because urine is often supersaturated with oxalate, crystal formation depends on factors such as pH, concentration, and the balance between promoters and inhibitors like citrate. Stone formation begins with nucleation, followed by crystal growth, aggregation, and retention within renal tubules, especially in areas of slow urine flow. Increased urinary oxalate markedly raises stone risk and promotes nephrocalcinosis, where crystals deposit in renal tissue. These deposits trigger inflammation, tubular injury, and fibrosis, leading to progressive renal damage. With declining kidney function, oxalate accumulates further, accelerating injury and potentially progressing to end-stage renal disease.

The diagnosis and management of hyperoxaluria focus on identifying underlying causes, confirming elevated oxalate levels, and preventing complications such as Calcium oxalate nephrolithiasis. Patients presenting with renal colic are initially evaluated with urinalysis and noncontrast CT scan, the gold standard for detecting stones, while stone composition analysis helps determine etiology. Definitive evaluation requires a 24-hour urine collection to measure oxalate and other urinary parameters, with normal oxalate levels ≤40 mg/day and higher values suggesting dietary or primary causes. Markedly elevated levels (>75-100 mg/day), early-onset stones, recurrent calculi, or nephrocalcinosis raise suspicion for primary hyperoxaluria, which can be confirmed through genetic testing or enzyme assays.

Management includes both acute stone treatment and long-term preventive strategies. Increased fluid intake to achieve urine output of at least 3 L/day is essential to reduce supersaturation. Potassium citrate is used to increase urinary citrate and maintain a favorable pH, thereby inhibiting crystal formation. Dietary modifications are important in secondary hyperoxaluria, including reducing oxalate-rich foods, limiting excess vitamin C, maintaining adequate calcium intake, and lowering sodium and animal protein consumption. Pharmacologic therapies such as pyridoxine (vitamin B6) can reduce oxalate production, particularly in some patients with primary hyperoxaluria, while supplements like magnesium, orthophosphates, or calcium citrate help bind oxalate in the gut.

"Hyperoxaluria - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperoxaluria pipeline landscape is provided which includes the disease overview and Hyperoxaluria treatment guidelines. The assessment part of the report embraces, in depth Hyperoxaluria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperoxaluria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hyperoxaluria R&D. The therapies under development are focused on novel approaches to treat/improve Hyperoxaluria.

Hyperoxaluria Emerging Drugs Chapters

This segment of the Hyperoxaluria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperoxaluria Emerging Drugs

• ABO-101: Arbor Biotechnologies

ABO-101 is a novel, investigational gene editing medicine designed to be a one-time liver-directed gene editing treatment that results in a permanent loss of function of the HAO1 gene in the liver to reduce oxalate production. ABO-101 consists of a lipid nanoparticle (LNP), licensed from Acuitas Therapeutics, encapsulating messenger RNA expressing a novel Type V CRISPR Cas12i2 nuclease and an optimized guide RNA which specifically targets the human HAO1 gene. ABO-101 has received orphan drug (ODD) and rare pediatric disease designation (RPDD) from the FDA for the treatment of PH1. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Hyperoxaluria.

Hyperoxaluria: Therapeutic Assessment

This segment of the report provides insights about the different Hyperoxaluria drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperoxaluria

• There are approx. 3+ key companies which are developing the therapies for Hyperoxaluria. The companies which have their Hyperoxaluria drug candidates in the early stage, i.e. phase I/II include, Arbor Biotechnologies.

Phases

The report covers around 3+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperoxaluria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperoxaluria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperoxaluria drugs.

Hyperoxaluria Report Insights

• Hyperoxaluria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperoxaluria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperoxaluria drugs?
• How many Hyperoxaluria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperoxaluria?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperoxaluria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperoxaluria and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arbor Biotechnologies
• META Pharmaceuticals
• Biocodex

Key Products

• ABO-101
• META 001 PH
• Stiripentol

This product will be delivered within 2 business days.